Company Overview
NovMetaPharma is a company that develops first-in-class drugs with differentiated mechanisms (activation of AMPK Sirt 1 and Nrf2 pathways) using new substances. We will lead the global metabolic syndrome medication market through ingenious technology and efficient development systems.
01
Technology
Possessing an novel technology of first-in-class metabolic syndrome medication
02
Extensibility
Securing various additional pipelines related to metabolic diseases
03
Business Value
NovMetaPharma is developing type 2 diabetes medication NovDB2, anti-obesity medication NovOB, chronic kidney disease medication NovRD, fibrosis medication NovFS, and retroperitoneal fibrosis medication NovRF.
Type 2 Diabetes
-
-
No. of Patients
- 629M
(17’)
-
-
-
Market Size
- $37.3B
(18’)
-
-
-
Predicted Market Size
- $55.7B
(22’)
-
Obesity
-
-
No. of Patients - 1.9B
(17’)
-
-
-
Market Size - $1.7B
(18’)
-
-
-
Predicted Market Size - $4.7B
(22’)
-
Chronic Kidney Disease
-
-
No. of Patients - 697.5M
(17’)
-
-
-
Market Size - $12.9B
(18’)
-
-
-
Predicted Market Size - $14.5B
(22’)
-
Fibrosis *
-
-
No. of Patients - 5M
(17’)
-
-
-
Market Size - $1.6B
(16’)
-
-
-
Predicted Market Size - $3.5B
(23’)
-
Retroperitoneal Fibrosis **
-
-
No. of Patients - 0.27M
(15’)
-
-
-
Market Size - $3.6M
(17’)
-
-
-
Predicted Market Size - $5B
(25’)
-
*Fibrosis related figures in the table above are based on idiopathic pulmonary fibrosis.
**Retroperitoneal fibrosis related figures are based on the number of peritoneal dialysis patients.